There are currently 22 active clinical trials seeking participants for Myasthenia Gravis research studies. The states with the highest number of trials for Myasthenia Gravis participants are California, Florida, Texas and Ohio.
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT06414954
Recruiting
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: Profound Research LLC, Carlsbad, California +36 locations
Conditions: Myasthenia Gravis, Myasthenia Gravis, MuSK
Register for Updates
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
NCT05265273
Recruiting
The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (\<) 18 years of age (globally) and 8 to \<18 years of age (for Unites Stated (US) sites only), the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
04/09/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +18 locations
Conditions: Myasthenia Gravis
Register for Updates
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622
Recruiting
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Neuromuscular Research Center and Clinic, Paradise Valley, Arizona +110 locations
Conditions: Myasthenia Gravis
Register for Updates
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201
Recruiting
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/02/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +37 locations
Conditions: Multiple Sclerosis, Myasthenia Gravis
Register for Updates
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT06298565
Recruiting
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: SFM Clinical Research, LLC, Boca Raton, Florida +5 locations
Conditions: Myasthenia Gravis
Register for Updates
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis
NCT06193889
Recruiting
A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Myasthenia Gravis
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/20/2025
Locations: University of California, Irvine, Orange, California +10 locations
Conditions: Myasthenia Gravis, Generalized Myasthenia Gravis
Register for Updates
Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
NCT06866483
Recruiting
This study expands and validates the pilot study NCT06381284. It is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The primary objective is to determine the validity of a self-assessment tool in encouraging undiagnosed participants, recruited through a social media campaign, to seek medical evaluation for suspected myasthenia gravis (MG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: ZS Associates, Evanston, Illinois
Conditions: Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations
Register for Updates
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy And/or Breastfeeding.
NCT06299748
Recruiting
This is a multi-country, prospective safety study of pregnant women exposed to efgartigimod or efgartigimod PH20 SC any time within 25 days prior to conception or any time during pregnancy. Women exposed to efgartigimod or efgartigimod PH20 SC only during breastfeeding will also be eligible to enroll. Background rates of major congenital malformations (MCMs) will be obtained from populations within the same countries/regions as the countries/regions in which the efgartigimod or efgartigimod PH20... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
02/26/2025
Locations: United BioSource LLC, Morgantown, West Virginia
Conditions: Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects with Myasthenia Gravis
NCT06106672
Recruiting
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/12/2025
Locations: Barrow Neurological Institute, Phoenix, Arizona +16 locations
Conditions: Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
Register for Updates
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
NCT06626919
Recruiting
A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: University of California, Irvine, Orange, California
Conditions: Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness
Register for Updates
Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
NCT06491238
Recruiting
The overall purpose of this pilot study is to examine the feasibility, acceptability, and tolerability of light and moderate intensity exercise in adults with MGeffect of light vs. moderate intensity exercise on health outcomes. Participants will be enrolled into the NeuroWell exercise program, which is geared toward individuals with neurological disorders or injuries and led by Certified Exercise Physiologists (CEPs) at the HealthPartners Neuroscience Center. A total of 20 people with MG will b... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/08/2025
Locations: HealthPartners Neuroscience Center, Saint Paul, Minnesota
Conditions: Myasthenia Gravis
Register for Updates
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
NCT06539169
Recruiting
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in the study by electronic consent (eConsent) and sign a medical records release to permit data collection. Medical records are accessed from institutions directly via eFax or paper fax, online from patient electronic medical record (EMR) portals, direct from DNA/RNA sequencing and molecular profiling vendors, and via elect... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/12/2024
Locations: xCures, Los Altos, California
Conditions: Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Register for Updates